阿伐曲泊帕提高肝病所致血小板减少症患者的血小板计数但不增加血小板活化
这项随机双盲安慰剂对照平行组研究纳入慢性肝病合并血小板减少症患者,评估阿伐曲泊帕对血小板活化的影响。全血流式细胞术检测显示,阿伐曲泊帕组血小板计数升高,但循环活化血小板数量及对ADP和凝血酶受体激活肽的血小板反应性均未较安慰剂组增加。
要点
- 阿伐曲泊帕提高慢性肝病合并血小板减少症患者的血小板计数。
- 阿伐曲泊帕未增加体内循环活化血小板数量。
- 阿伐曲泊帕未增加体外对ADP和凝血酶受体激活肽的血小板反应性。
核心结论
- 在慢性肝病合并血小板减少症患者中,阿伐曲泊帕提高血小板计数,但未增加体内血小板活化或体外血小板反应性。
研究设计与样本
- 随机、双盲、安慰剂对照、平行组研究,纳入慢性肝病合并血小板减少症患者。
- 研究采血前10天内无患者接受血小板输注。
- 采用全血流式细胞术评估血小板活化,该方法在血小板减少样本中准确。
主要发现
- 阿伐曲泊帕组血小板计数升高,安慰剂组未升高。
- 以血小板表面P-选择素和活化糖蛋白IIb-IIIa测量,阿伐曲泊帕组循环活化血小板数量较安慰剂组未增加。
- 阿伐曲泊帕组对低浓度和高浓度ADP及凝血酶受体激活肽的血小板反应性较安慰剂组未增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Thrombopoietin (TPO) lowers the threshold for platelet activation. TPO receptor agonists (RAs) may therefore also lead to platelet activation. Patients with chronic liver disease and thrombocytopenia participated in a randomized trial. The TPO-RA avatrombopag did not increase platelet activation in vivo or reactivity in vitro. BACKGROUND: The thrombopoietin (TPO) receptor agonist (TPO-RA) avatrombopag has recently been Food and Drug Administration-approved for the treatment of thrombocytopenia in patients with chronic liver disease (CLD) scheduled for a procedure. The TPO receptor c-mpl is expressed on the platelet surface, and TPO lowers the threshold for platelet activation. TPO-RAs may therefore also lead to platelet activation. OBJECTIVES: To evaluate the effects of avatrombopag on platelet activation. PATIENTS/METHODS: CLD patients with thrombocytopenia participated in a randomized, double-blind, placebo-controlled, parallel-group study. No patient received a platelet transfusion within 10 days of study blood draws. Platelet activation was evaluated with whole blood flow cytometry (which, unlike other methods, is accurate in thrombocytopenic samples). RESULTS: Avatrombopag, but not placebo, increased platelet counts. As measured by platelet surface P-selectin and activated glycoprotein IIb-IIIa: (i) the numbers of circulating activated platelets were not increased in avatrombopag-treated patients as compared with placebo-treated patients; and (ii) platelet reactivity to low and high concentrations of ADP and thrombin receptor-activating peptide was not increased in avatrombopag-treated patients as compared with placebo-treated patients. CONCLUSIONS: In this randomized, double-blind, placebo-controlled, parallel-group study of CLD patients with thrombocytopenia, avatrombopag increased platelet counts but did not increase platelet activation in vivo or platelet reactivity in vitro.
引用
- Michelson AD, Smolensky Koganov E, Forde EE, et al. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018. PMID: 30264918. doi:10.1111/jth.14295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。